HIPRAGUMBORO BPL2

Inactivated vaccine against Gumboro disease and Newcastle disease, in injectable emulsion

COMPOSITION PER DOSE:

Inactivated Newcastle Disease Virus, strain La Sota, HAI ­ 1/16 Inactivated Gumboro Disease Virus, strain W2512, ELISA ­ 357 The need to vaccinate breeding hens with adjuvanted vaccines against Gumboro Disease has already been discussed over the last few years since it is very important to be able to increase immunity against this disease in offspring. Studies carried out have determined that the best age for using adjuvanted Gumboro vaccines is the period before laying. Normally, hens are also vaccinated against Newcastle Disease before laying by using adjuvanted vaccines to increase immunity during a large part of the productive period of the bird. Bearing this in mind and given that handling is very important in aviculture, we believe it is convenient and of great interest to be able to immunise simultaneously against Gumboro and Newcastle Diseases, using a duly adjuvanted mixed vaccine which contains both antigens. In this way we can simplify the vaccination programme chosen and reduce both labour costs and the habitual stress in layers and breeders.

INDICATIONS FOR USE:

Young hens, future layers and breeders: Prevention and control of Newcastle Disease and Gumboro Disease.

POSOLOGY: Young hens, future layers and breeders: 1 dose of 0.5 ml/bird.

ADMINISTRATION ROUTE:

Intramuscular injection in the breast muscles, or subcutaneous injection in the dorsal midline of the neck.

OBSERVATIONS:

In general, it is recommended to vaccinate future layers and breeders before laying (18 weeks), although under veterinary prescription, the vaccine can be administered at any time during the breeding and rebreeding period, revaccinating before laying (18 weeks).

ADVERSE EFFECTS: None.

SPECIAL PRECAUTIONS FOR USE:

Only vaccinate healthy animals. Since the vaccine is packaged in a multidose bottle, the entire contents of the vaccine should be used once the bottle has been opened. Shake well before use. Use sterile material for its administration. Administer the vaccine at a temperature between +15 ºC and +25 ºC. Store between +2 and +8 ºC, protected from the light, avoiding possible freezing.

CONTRAINDICATIONS: None known.

SPECIAL PRECAUTIONS:

To the user:

This product contains mineral oil. Accidental injection (self-injection) may result in severe pain and swelling, particularly if injected into a joint or ‑nger, and in rare cases could result in the loss of the affected ‑nger if prompt medical attention is not given. If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, results in ischemic necrosis and even the loss of a digit. PROMPT expert, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where ‑nger pulp or tendon is involved.

WITHDRAWAL PERIOD: Zero days.

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED MEDICINAL PRODUCT

OR WASTE MATERIALS, IF ANY:

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

PRESENTATION:

Bottle with 500 doses (250 ml).

Bottle with 1,000 doses (500 ml).